Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

Volume: 377, Issue: 9, Pages: 829 - 838
Published: Jun 6, 2017
Abstract
BackgroundAlectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-positive non–small-cell lung cancer (NSCLC). We investigated alectinib as compared with crizotinib in patients with previously untreated, advanced ALK-positive NSCLC, including those with asymptomatic CNS disease. MethodsIn a randomized, open-label, phase 3 trial, we randomly...
Paper Fields
Paper Details
Title
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
Published Date
Jun 6, 2017
Volume
377
Issue
9
Pages
829 - 838
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.